Synspira expands accord with Cystic Fibrosis Foundation
Privately-held US biopharma company Synspira Therapeutics today announced that the Cystic Fibrosis Foundation has made equity and structured investments in the company of up to $14 million in additional funding.
The new funding brings the Foundation's total commitment to $22.55 million. In addition, the Miller Family Trust, a founding investor in Synspira, will continue to invest along with the CF Foundation.
"This investment and development collaboration will enable Synspira to complete pre-clinical and initial clinical development for SNSP003 while also advancing SNSP113 through late stage clinical studies," said Robert Gallotto, Synspira's president and chief executive, adding: "Our many longstanding collaborations with the CF Foundation underscores our commitment and mutual sense of urgency as we work to bring life-changing therapies to people living with CF and other serious rare disorders."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze